title: Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder - experience from a specialty clinic in India.
abstract: OBJECTIVE
  To study the effectiveness and tolerability of aripiprazole augmentation in patients with highly treatment-resistant obsessive-compulsive disorder (OCD) in a real-world scenario.
  
  
  METHODS
  We conducted a chart review of patients who were initiated on aripiprazole augmentation at a specialty OCD clinic in India between 2004 and 2014. Primary outcome measure was all-cause discontinuation.
  
  
  RESULTS
  23 patients were eligible for analysis. Patients had not achieved symptom remission despite a mean of over 3 prior SRI trials. Aripiprazole was continued to be used in seven patients (30%) at the time of last follow-up. Thirteen patients (57%) discontinued the drug due to side effects, and three patients (13%) discontinued aripiprazole citing no improvement. Six patients (26%) were noted to have ≥25% reduction on the Yale-Brown Obsessive-Compulsive Scale.
  
  
  CONCLUSIONS
  The study demonstrated, in a real-world setting, that aripiprazole may be a useful augmenting agent in a proportion of patients with highly treatment-resistant OCD. However, side effects may lead to premature discontinuation in many of them.
authors.affiliation: a OCD Clinic, Department of Psychiatry , National Institute of Mental Health and Neurosciences (NIMHANS) , Bangalore , India.
authors.forename: Aditya
authors.initials: A
authors.lastname: Hegde
authors.affiliation: a OCD Clinic, Department of Psychiatry , National Institute of Mental Health and Neurosciences (NIMHANS) , Bangalore , India.
authors.forename: Bangalore G
authors.initials: BG
authors.lastname: Kalyani
authors.affiliation: a OCD Clinic, Department of Psychiatry , National Institute of Mental Health and Neurosciences (NIMHANS) , Bangalore , India.
authors.forename: Shyam Sundar
authors.initials: SS
authors.lastname: Arumugham
authors.affiliation: a OCD Clinic, Department of Psychiatry , National Institute of Mental Health and Neurosciences (NIMHANS) , Bangalore , India.
authors.forename: Janardhanan C
authors.initials: JC
authors.lastname: Narayanaswamy
authors.affiliation: a OCD Clinic, Department of Psychiatry , National Institute of Mental Health and Neurosciences (NIMHANS) , Bangalore , India.
authors.forename: Suresh Bada
authors.initials: SB
authors.lastname: Math
authors.affiliation: a OCD Clinic, Department of Psychiatry , National Institute of Mental Health and Neurosciences (NIMHANS) , Bangalore , India.
authors.forename: Y C Janardhan
authors.initials: YC
authors.lastname: Reddy
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000068180:Aripiprazole / Q000008:administration & dosage / Q000494:pharmacology*; D004351:Drug Resistance; D004357:Drug Synergism; D005260:Female; D005500:Follow-Up Studies; D006782:Hospitals, Special; D006801:Humans; D007194:India; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D000068180:Aripiprazole; D017367:Selective Serotonin Reuptake Inhibitors
keywords: Aripiprazole; OCD; augmentation; obsessive–compulsive disorder; resistant